Cantor Fitzgerald Expects Weaker Earnings for Sanara MedTech

Sanara MedTech Inc. (NASDAQ:SMTI) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Sanara MedTech in a report issued on Thursday, November 13th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($2.92) per share for the year, down from their previous estimate of ($0.88). The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. Cantor Fitzgerald also issued estimates for Sanara MedTech’s FY2026 earnings at $1.72 EPS.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.33. The business had revenue of $26.33 million during the quarter, compared to the consensus estimate of $26.63 million. Sanara MedTech had a negative return on equity of 21.33% and a negative net margin of 36.79%.

SMTI has been the topic of several other research reports. Wall Street Zen lowered shares of Sanara MedTech from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. HC Wainwright reduced their target price on Sanara MedTech from $54.00 to $36.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $41.00.

Sanara MedTech Price Performance

SMTI stock opened at $20.90 on Monday. The company’s 50-day moving average price is $29.94 and its two-hundred day moving average price is $29.70. The firm has a market cap of $186.01 million, a P/E ratio of -4.95 and a beta of 1.21. The company has a quick ratio of 1.60, a current ratio of 1.80 and a debt-to-equity ratio of 7.34. Sanara MedTech has a 12 month low of $19.10 and a 12 month high of $38.75.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its stake in shares of Sanara MedTech by 14.9% in the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after acquiring an additional 483 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Sanara MedTech by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 13,880 shares of the company’s stock worth $428,000 after purchasing an additional 826 shares in the last quarter. Bank of America Corp DE raised its position in Sanara MedTech by 44.1% in the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after purchasing an additional 973 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Sanara MedTech by 351.7% during the third quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after purchasing an additional 1,171 shares in the last quarter. Finally, Stephens Inc. AR grew its holdings in shares of Sanara MedTech by 18.0% during the second quarter. Stephens Inc. AR now owns 12,794 shares of the company’s stock worth $363,000 after purchasing an additional 1,952 shares during the last quarter. 8.10% of the stock is currently owned by institutional investors and hedge funds.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.